INFU
InfuSystem Holdings, Inc.9.29
+0.05+0.54%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A fleshes out guidance details
Q&A elaborated on 6-8% revenue guidance, pinpointing Patient Services—led by Wound Care PCDs and Oncology—as the main driver, while Device Solutions offsets GE contract losses ($7.1M revenue hit) with higher-margin wins. ERP project wraps Q1 with elevated spend but nets $2M annual savings thereafter; no extra costs to migrate RCM to Oncology. ChemoMouthpiece billing awaits CMS word, excluded from guidance low-end but upside potential. New DME accreditations include Defender Boot and HidraWear ostomy product. Capital allocation sticks to opportunistic buybacks, flexible debt paydown, business investment, and M&A. Management dodged quantifying new product ramps. Q&A reaffirms profitable growth tone; investors watch Wound Care scaling, ERP payoffs.
Key Stats
Market Cap
189.76MP/E (TTM)
35.73Basic EPS (TTM)
0.26Dividend Yield
0%Recent Filings
10-K
FY2025 results
InfuSystem Holdings posted FY2025 net revenues of $143.4M, up 6.4% y/y, with Patient Services climbing 7.7% to $86.5M on oncology and wound care volume while Device Solutions edged 4.4% higher to $56.9M via rentals and services. Gross margin leaped to 56.0% from 52.2%, fueling operating income of $11.9M versus $6.9M prior year—Q4 buybacks accelerated, retiring 138K shares at ~$9.40. Cash flow from operations hit $24.4M. Yet third-party reimbursement shifts threaten quarterly momentum.
8-K
2025 results: $143M revenue
InfuSystem released its February 27, 2026 investor presentation under Regulation FD, spotlighting 2025 results: $143.4M revenue, up from $134.9M in 2024, with adjusted EBITDA hitting $31.5M and 21.9% margins. Patient Services drove 60% of revenues at $86.5M; Device Solutions added $56.9M. Solid balance sheet shows 0.52x net leverage. Growth hinges on biomedical and wound care.
8-K
Record revenues, EBITDA up 24%
InfuSystem reported record 2025 net revenues of $143.4 million, up 6%, with net income surging 183% to $6.6 million and Adjusted EBITDA climbing 24% to $31.5 million. Patient Services grew 8% while Device Solutions rose 4%; operating cash flow hit $24.4 million. Restructured largest biomedical contract cuts 2026 revenue by $7.1 million but boosts margins. Pro-forma revenue growth: 6-8%. Wound Care exploded 160% in Q4.
8-K
CMS approves InfuSystem pumps for NOPAIN pay
InfuSystem Holdings announced CMS added its CADD-Solis and Sapphire infusion pumps to the NOPAIN Act's qualifying list for separate Medicare payments up to $1,997.16 starting January 1, 2026, through 2027 in HOPD/ASC settings. This bolsters non-opioid pain management post-surgery. CEO sees growth catalyst, yet outlook tempered pending reimbursement details and customer adoption.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
ICUI
ICU Medical, Inc.
147.07-0.96
ISRG
Intuitive Surgical, Inc.
554.58-4.94
KRMD
KORU Medical Systems, Inc.
5.77-0.04
MMSI
Merit Medical Systems, Inc.
86.85+0.44
NSYS
Nortech Systems Incorporated
7.17+0.18
NUWE
Nuwellis, Inc.
2.21+0.03
SOLV
Solventum Corporation
80.59-1.30
TFX
Teleflex Incorporated
124.87-1.85
WST
West Pharmaceutical Services, I
266.44-5.42